Last reviewed 2026-04-20 · How we verify

Furenazin (NIFURPRAZINE)

Phase 2 active Small molecule

Furenazin (generic name: NIFURPRAZINE) is a nifurprazine drug. It is currently in Phase 2 development.

Furenazin works by inhibiting the growth of microorganisms through its antimicrobial properties.

Furenazin, also known as Nifurprazine, is a small molecule drug in the nifurprazine class. Unfortunately, there is limited information available on this compound. It is not clear what specific target or indication it is intended to treat. The commercial status of Furenazin is also unknown, and it may not be FDA-approved. Further research is needed to determine its safety and efficacy.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NIFURPRAZINE
Drug class	nifurprazine
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of Furenazin like a strong disinfectant for your body. It helps to stop the growth of bad bacteria, viruses, and other microorganisms that can cause infections. This helps to prevent the spread of infection and promote healing.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Furenazin CI brief — competitive landscape report
Furenazin updates RSS · CI watch RSS

Frequently asked questions about Furenazin

What is Furenazin?

Furenazin (NIFURPRAZINE) is a nifurprazine drug.

How does Furenazin work?

Furenazin works by inhibiting the growth of microorganisms through its antimicrobial properties.

What is the generic name of Furenazin?

NIFURPRAZINE is the generic (nonproprietary) name of Furenazin.

What drug class is Furenazin in?

Furenazin belongs to the nifurprazine class. See all nifurprazine drugs at /class/nifurprazine.

What development phase is Furenazin in?

Furenazin is in Phase 2.

Drug class: All nifurprazine drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing